Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/72582
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tully, P. | - |
dc.contributor.author | Cardinal, T. | - |
dc.contributor.author | Bennetts, J. | - |
dc.contributor.author | Baker, R. | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Heart Lung and Circulation, 2012; 21(4):206-214 | - |
dc.identifier.issn | 1443-9506 | - |
dc.identifier.issn | 1444-2892 | - |
dc.identifier.uri | http://hdl.handle.net/2440/72582 | - |
dc.description.abstract | <h4>Background</h4>No Australian study has reported the association between selective-serotonin reuptake inhibitor (SSRI) and serotonin noradrenaline reuptake inhibitor (SNRI) with coronary artery bypass graft (CABG) surgery morbidity and mortality.<h4>Methods</h4>4136 patients underwent CABG surgery between January 1996 and December 2008 and 105 (2.5%) were SSRI/SNRI users. Bleeding events included platelet, fresh frozen plasma and packed red blood cell transfusion, reoperation for bleeding and gastrointestinal bleeding. In-hospital morbidity included renal failure, stroke, ventilation >24h, deep sternal wound infection, reoperation (any cause), myocardial infarction and mortality.<h4>Results</h4>Median follow-up was 4.7 years (interquartile range, 2.3-7.9 years) and there were 727 deaths (17.6% of total). Use of SSRI/SNRI was associated with new requirement for renal dialysis (adjusted OR = 2.18; 95% CI, 1.06-4.45, p = .03) and ventilation >24h (adjusted OR = 1.69; 95% CI, 1.03-2.78, p = .04). Neither SSRI/SNRI use nor SSRI/SNRI and concomitant anti-platelet medication increased the odds for any bleeding events (all p>.20). No association was evident with all-cause mortality (adjusted hazard ratio = 1.60; 95% CI .59-4.35, p = .36), or cardiac mortality (adjusted hazard ratio = .31; 95% CI, .04-2.26, p = .25).<h4>Conclusions</h4>SSRI/SNRI users experienced an increased risk of renal dysfunction and prolonged ventilation, but not bleeding events or long-term mortality after CABG surgery. | - |
dc.description.statementofresponsibility | Phillip J. Tully, Tess Cardinal, Jayme S. Bennetts, and Robert A. Baker | - |
dc.language.iso | en | - |
dc.publisher | Blackwell Publishing Asia | - |
dc.rights | Crown copyright © 2012 Published by Elsevier Ltd. on behalf of The Australasian Society of Cardiac and Thoracic Surgeons and The Cardiac Society of Australia and New Zealand All rights reserved. | - |
dc.source.uri | http://dx.doi.org/10.1016/j.hlc.2011.12.002 | - |
dc.subject | Coronary artery bypass | - |
dc.subject | Antidepressive agents | - |
dc.subject | Depression | - |
dc.subject | Depressive disorder | - |
dc.subject | Mortality | - |
dc.subject | Morbidity | - |
dc.title | Selective serotonin reuptake inhibitors, Venlafaxine and Duloxetine are associated with in hospital morbidity but not bleeding or late mortality after coronary artery bypass graft surgery | - |
dc.type | Journal article | - |
dc.identifier.doi | 10.1016/j.hlc.2011.12.002 | - |
pubs.publication-status | Published | - |
dc.identifier.orcid | Tully, P. [0000-0003-2807-1313] | - |
Appears in Collections: | Aurora harvest 5 Psychology publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.